HTRA3
Serine protease HTRA3
Protein Summary
Serine protease that cleaves beta-casein/CSN2 as well as several extracellular matrix (ECM) proteoglycans such as decorin/DCN, biglycan/BGN and fibronectin/FN1. Inhibits signaling mediated by TGF-beta family proteins possibly indirectly by degradation of these ECM proteoglycans (By similarity). May act as a tumor suppressor. Negatively regulates, in vitro, trophoblast invasion during placental development and may be involved in the development of the placenta in vivo. May also have a role in ovarian development, granulosa cell differentiation and luteinization (PubMed:21321049, PubMed:22229724).
- ENST00000307358
- ENSP00000303766
- ENSG00000170801
- ENST00000382512
- ENSP00000371952
- PRSP
- Prsp
- Tasp
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein domain | 0.85 | ||
small molecule perturbation | 0.58 | ||
tissue | 0.58 | ||
cell line | 0.55 | ||
tissue sample | 0.5 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 15.66 (req: < 5)
Gene RIFs: 43 (req: <= 3)
Antibodies: 100 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 15.66 (req: >= 5)
Gene RIFs: 43 (req: > 3)
Antibodies: 100 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0